Johnson & Johnson (JNJ) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Johnson & Johnson (JNJ) trades at a price-to-earnings ratio of 42.9x, with a stock price of $248.43 and trailing twelve-month earnings per share of $10.34.
The current P/E is 95% above its 5-year average of 22.0x. Over the past five years, JNJ's P/E has ranged from a low of 9.6x to a high of 33.5x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, JNJ trades at a 81% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, JNJ commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our JNJ DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Large diversified branded pharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
LLYEli Lilly and Company | $942B | 89.9 | 14.62 | +102% |
JNJJohnson & Johnson | $599B | 42.9Lowest | - | -58% |
AZNAstraZeneca PLC | $323B | 63.7 | 2.92Best | +189%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | Sun Sep 28 2025 00:00:00 GM | $179.71 | $10.36 | 17.3x | -44% |
| FY2025 Q2 | Sun Jun 29 2025 00:00:00 GM | $152.41 | $9.35 | 16.3x | -47% |
| FY2025 Q1 | Sun Mar 30 2025 00:00:00 GM | $163.71 | $8.99 | 18.2x | -41% |
| FY2024 Q4 | Sun Dec 29 2024 00:00:00 GM | $145.05 | $5.79 | 25.1x | -19% |
| FY2024 Q3 | Sun Sep 29 2024 00:00:00 GM | $161.40 | $6.05 | 26.7x | -13% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $146.16 | $15.15 | 9.6x | -69% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $158.19 | $15.18 | 10.4x | -66% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $156.74 | $13.81 | 11.3x | -63% |
| FY2023 Q3 | Sun Oct 01 2023 00:00:00 GM | $155.75 | $13.47 | 11.6x | -62% |
| FY2023 Q2 | Sun Jul 02 2023 00:00:00 GM | $165.52 | $4.94 | 33.5x | +9% |
| FY2023 Q1 | Sun Apr 02 2023 00:00:00 GM | $155.00 | $4.78 | 32.4x | +5% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $176.65 | $6.74 | 26.2x | -15% |
Average P/E for displayed period: 30.8x
See JNJ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JNJ Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare JNJ vs AGIO
See how JNJ stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is JNJ stock overvalued or undervalued?
JNJ trades at 42.9x P/E, above its 5-year average of 22.0x. The 100th percentile ranking indicates a premium to historical valuation.
How does JNJ's valuation compare to peers?
Johnson & Johnson P/E of 42.9x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is JNJ's PEG ratio?
JNJ PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.